7.4M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 8,334 | 0 | - | - | Restricted Stock Units | |
| Raj K. Puri | Chief Regulatory Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.59 per share. | 14 Mar 2025 | 2,509 | 201,252 (0%) | 0% | 3.6 | 9,007 | Common Stock |
| Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 8,334 | 203,761 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 93,750 | 93,750 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 187,500 | 187,500 | - | - | Restricted Stock Units | |
| Jean-Marc Bellemin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 93,750 | 93,750 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 93,750 | 93,750 | - | - | Restricted Stock Units | |
| Raj K. Puri | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 117,190 | 117,190 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 62,106 | 120,880 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.04 per share. | 03 Mar 2025 | 33,302 | 87,578 (0%) | 0% | 4.0 | 134,540 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 3,516 | 14,065 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 58,590 | 70,317 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.04 per share. | 03 Mar 2025 | 95,413 | 349,646 (0%) | 0% | 4.0 | 385,469 | Common Stock |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 213,525 | 333,350 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 10,418 | 41,669 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 223,943 | 445,059 (0%) | 0% | 0 | Common Stock | |
| Jean-Marc Bellemin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 58,590 | 87,938 (0%) | 0% | 0 | Common Stock | |
| Jean-Marc Bellemin | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.04 per share. | 03 Mar 2025 | 31,734 | 56,204 (0%) | 0% | 4.0 | 128,205 | Common Stock |
| Jean-Marc Bellemin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 58,590 | 70,317 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 62,497 | 126,383 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 58,590 | 70,317 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.04 per share. | 03 Mar 2025 | 33,470 | 92,913 (0%) | 0% | 4.0 | 135,219 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 3,907 | 15,626 | - | - | Restricted Stock Units | |
| Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 59,999 | 43,756 | - | - | Restricted Stock Units | |
| Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 59,999 | 215,411 (0%) | 0% | 0 | Common Stock | |
| Raj K. Puri | Chief Regulatory Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.04 per share. | 03 Mar 2025 | 19,984 | 195,427 (0%) | 0% | 4.0 | 80,735 | Common Stock |
| Daniel Gordon Kirby | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 35,000 | 35,000 | - | - | Stock Options (Right to Buy) | |
| Daniel Gordon Kirby | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 150,000 | 150,000 | - | - | Performance Stock Units | |
| Daniel Gordon Kirby | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 120,000 | 120,000 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 2,813 | 60,352 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 2,813 | 0 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.89 per share. | 14 Jan 2025 | 1,578 | 58,774 (0%) | 0% | 5.9 | 9,294 | Common Stock |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 20,835 | 0 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 20,835 | 231,071 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.89 per share. | 14 Jan 2025 | 9,955 | 221,116 (0%) | 0% | 5.9 | 58,635 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 2,813 | 65,464 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 2,813 | 0 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.89 per share. | 14 Jan 2025 | 1,578 | 63,886 (0%) | 0% | 5.9 | 9,294 | Common Stock |
| Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 8,334 | 8,334 | - | - | Restricted Stock Units | |
| Raj K. Puri | Chief Regulatory Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.84 per share. | 16 Dec 2024 | 3,759 | 155,412 (0%) | 0% | 7.8 | 29,471 | Common Stock |
| Raj Puri K. | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 8,334 | 159,171 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 3,516 | 59,323 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 3,516 | 17,581 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share. | 02 Dec 2024 | 1,784 | 57,539 (0%) | 0% | 9.1 | 16,181 | Common Stock |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 10,417 | 214,662 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share. | 02 Dec 2024 | 4,426 | 210,236 (0%) | 0% | 9.1 | 40,144 | Common Stock |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 10,417 | 52,087 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 3,906 | 64,633 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 3,906 | 19,533 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share. | 02 Dec 2024 | 1,982 | 62,651 (0%) | 0% | 9.1 | 17,977 | Common Stock |
| Ryan D. Maynard | Director | Sale of securities on an exchange or to another person at price $ 10.06 per share. | 12 Nov 2024 | 50,000 | 7,500 (0%) | 0% | 10.1 | 503,000 | Common Stock |
| Ryan D. Maynard | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| Ryan D. Maynard | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.45 per share. | 12 Nov 2024 | 50,000 | 57,500 (0%) | 0% | 7.5 | 372,500 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 2,813 | 2,813 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 2,813 | 57,235 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.77 per share. | 14 Oct 2024 | 1,428 | 55,807 (0%) | 0% | 9.8 | 13,952 | Common Stock |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 20,834 | 213,096 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 20,834 | 20,835 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.77 per share. | 14 Oct 2024 | 8,851 | 204,245 (0%) | 0% | 9.8 | 86,474 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 2,813 | 2,813 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 2,813 | 62,155 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.77 per share. | 14 Oct 2024 | 1,428 | 60,727 (0%) | 0% | 9.8 | 13,952 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 3,516 | 44,659 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 23,438 | 23,437 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 3,516 | 21,097 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 11,891 | 54,422 (0%) | 0% | 10.8 | 129,017 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 23,438 | 66,313 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 1,784 | 42,875 (0%) | 0% | 10.8 | 19,356 | Common Stock |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 10,417 | 169,726 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 10,417 | 62,504 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 46,875 | 46,875 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 19,913 | 192,262 (0%) | 0% | 10.8 | 216,056 | Common Stock |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 46,875 | 212,175 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 4,426 | 165,300 (0%) | 0% | 10.8 | 48,022 | Common Stock |
| Jean-Marc Bellemin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 23,438 | 41,239 (0%) | 0% | 0 | Common Stock | |
| Jean-Marc Bellemin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 23,438 | 23,437 | - | - | Restricted Stock Units | |
| Jean-Marc Bellemin | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 11,891 | 29,348 (0%) | 0% | 10.8 | 129,017 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 11,891 | 59,342 (0%) | 0% | 10.8 | 129,017 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 23,438 | 71,233 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 3,907 | 49,778 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 1,983 | 47,795 (0%) | 0% | 10.9 | 21,516 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 23,438 | 23,437 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 3,907 | 23,439 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,813 | 42,571 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,813 | 5,626 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 15 Jul 2024 | 1,428 | 41,143 (0%) | 0% | 8.7 | 12,395 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 20,835 | 41,669 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 20,835 | 168,160 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 15 Jul 2024 | 8,851 | 159,309 (0%) | 0% | 8.7 | 76,827 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,813 | 47,299 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,813 | 5,626 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 15 Jul 2024 | 1,428 | 45,871 (0%) | 0% | 8.7 | 12,395 | Common Stock |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 49,303 | 49,303 | - | - | Deferred Restricted Stock Unit | |
| Michael Weiser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 49,303 | 49,303 | - | - | Deferred Restricted Stock Unit | |
| Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 49,303 | 49,303 | - | - | Deferred Restricted Stock Unit | |
| Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 49,303 | 49,303 | - | - | Deferred Restricted Stock Unit | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 98,607 | 98,607 | - | - | Deferred Restricted Stock Unit | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 3,516 | 41,542 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 3,516 | 24,613 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 03 Jun 2024 | 1,784 | 39,758 (0%) | 0% | 8.4 | 14,932 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 10,417 | 72,921 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 03 Jun 2024 | 4,426 | 147,325 (0%) | 0% | 8.4 | 37,046 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 10,417 | 151,751 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 3,906 | 46,468 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 3,906 | 27,346 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 03 Jun 2024 | 1,982 | 44,486 (0%) | 0% | 8.4 | 16,589 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 2,812 | 39,453 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 2,812 | 8,439 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.89 per share. | 15 Apr 2024 | 1,427 | 38,026 (0%) | 0% | 11.9 | 16,967 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.89 per share. | 15 Apr 2024 | 8,851 | 141,334 (0%) | 0% | 11.9 | 105,238 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 20,834 | 62,504 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 20,834 | 150,185 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.89 per share. | 15 Apr 2024 | 1,427 | 42,562 (0%) | 0% | 11.9 | 16,967 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 2,812 | 8,439 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 2,812 | 43,989 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 14,061 | 43,928 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 14,061 | 28,129 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.96 per share. | 04 Mar 2024 | 7,287 | 36,641 (0%) | 0% | 17.0 | 123,588 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 41,662 | 83,338 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.96 per share. | 04 Mar 2024 | 11,449 | 129,351 (0%) | 0% | 17.0 | 194,175 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 41,662 | 140,800 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 15,623 | 49,230 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 15,623 | 31,252 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.96 per share. | 04 Mar 2024 | 8,053 | 41,177 (0%) | 0% | 17.0 | 136,579 | Common Stock |
| Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 50,000 | - | - | Deferred Restricted Stock Unit | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 25,000 | 25,000 | - | - | Deferred Restricted Stock Unit | |
| Michael Weiser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 100,000 | 100,000 | - | - | Deferred Restricted Stock Unit | |
| Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 50,000 | - | - | Deferred Restricted Stock Unit | |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 105,470 | 105,470 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 46,875 | 46,875 | - | - | Restricted Stock Units | |
| Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 50,000 | - | - | Deferred Restricted Stock Unit | |
| Wayne Rothbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 100,000 | 100,000 | - | - | Deferred Restricted Stock Unit | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 100,000 | 100,000 | - | - | Deferred Restricted Stock Unit | |
| Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 93,750 | 93,750 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 500,000 | 500,000 | - | - | Restricted Stock Units | |
| Jean-Marc Bellemin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 46,875 | 46,875 | - | - | Restricted Stock Units | |
| Jean-Marc Bellemin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 105,470 | 105,470 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 105,470 | 105,470 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 46,875 | 46,875 | - | - | Restricted Stock Units | |
| Merrill McPeak A. | Director | Purchase of securities on an exchange or from another person at price $ 9.15 per share. | 20 Feb 2024 | 250,000 | 320,150 (0%) | 0% | 9.2 | 2,287,500 | Common Stock |
| Rothbaum Wayne | Director | Purchase of securities on an exchange or from another person at price $ 9.15 per share. | 20 Feb 2024 | 5,000,000 | 28,067,333 (22%) | 3% | 9.2 | 45,750,000 | Common Stock |
| D. Dukes Iain | Director | Purchase of securities on an exchange or from another person at price $ 9.15 per share. | 20 Feb 2024 | 32,000 | 54,000 (0%) | 0% | 9.2 | 292,800 | Common Stock |
| Frederick Vogt G. | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 16 Jan 2024 | 6,530 | 99,138 (0%) | 0% | 8.4 | 54,656 | Common Stock |
| Graf Friedrich Finckenstein | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 16 Jan 2024 | 1,577 | 33,607 (0%) | 0% | 8.4 | 13,199 | Common Stock |
| Bilinsky Igor | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 2,813 | 31,444 (0%) | 0% | 0 | Common Stock | |
| Vogt Frederick G. | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 20,834 | 83,338 | - | - | Restricted Stock Units | |
| G. Frederick Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 20,834 | 105,668 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Graf Friedrich | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 2,813 | 35,184 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Graf Friedrich | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 2,813 | 11,251 | - | - | Restricted Stock Units | |
| Bilinsky Igor | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 2,813 | 11,251 | - | - | Restricted Stock Units | |
| Bilinsky Igor | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 16 Jan 2024 | 1,577 | 29,867 (0%) | 0% | 8.4 | 13,199 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 2,813 | 28,608 (0%) | 0% | 0 | Common Stock | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 2,813 | 16,877 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.76 per share. | 14 Jul 2023 | 1,395 | 27,213 (0%) | 0% | 7.8 | 10,825 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 20,834 | 125,007 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.76 per share. | 14 Jul 2023 | 8,851 | 72,850 (0%) | 0% | 7.8 | 68,684 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 20,834 | 81,701 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.76 per share. | 14 Jul 2023 | 1,395 | 30,953 (0%) | 0% | 7.8 | 10,825 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 2,813 | 16,877 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 2,813 | 32,348 (0%) | 0% | 0 | Common Stock | |
| Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 51,955 | 51,955 | - | - | Deferred Restricted Stock Unit | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 12,988 | 12,988 | - | - | Deferred Restricted Stock Unit | |
| Michael Weiser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 51,955 | 51,955 | - | - | Deferred Restricted Stock Unit | |
| Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 51,955 | 51,955 | - | - | Deferred Restricted Stock Unit | |
| Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 51,955 | 51,955 | - | - | Deferred Restricted Stock Unit | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 103,911 | 103,911 | - | - | Deferred Restricted Stock Unit | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 74,823 | 74,823 | - | - | Deferred Restricted Stock Unit | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.64 per share. | 14 Apr 2023 | 1,395 | 25,795 (0%) | 0% | 5.6 | 7,868 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 2,812 | 19,690 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 2,812 | 27,190 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 20,834 | 69,718 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 20,834 | 145,841 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.64 per share. | 14 Apr 2023 | 8,851 | 60,867 (0%) | 0% | 5.6 | 49,920 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 2,812 | 30,930 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.64 per share. | 14 Apr 2023 | 1,395 | 29,535 (0%) | 0% | 5.6 | 7,868 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 2,812 | 19,690 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 84,380 | 84,380 | - | - | Stock Option (right to buy) | |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 42,190 | 42,190 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| Frederick G. Vogt | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 125,000 | 125,000 | - | - | Restricted Stock Units | |
| Jean-Marc Bellemin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 168,750 | 168,750 | - | - | Stock Option (right to buy) | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 93,750 | 93,750 | - | - | Stock Option (right to buy) | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 46,875 | 46,875 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.43 per share. | 17 Jan 2023 | 4,671 | 24,378 (0%) | 0% | 6.4 | 30,035 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 11,248 | 22,502 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 11,248 | 29,049 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 83,325 | 166,675 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 83,325 | 85,325 (0%) | 0% | 0 | Common Stock | |
| Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.43 per share. | 17 Jan 2023 | 36,441 | 48,884 (0%) | 0% | 6.4 | 234,316 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 11,248 | 32,796 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 11,248 | 22,502 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.43 per share. | 17 Jan 2023 | 4,678 | 28,118 (0%) | 0% | 6.4 | 30,080 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.11 per share. | 03 Jan 2023 | 10,553 | 17,801 (0%) | 0% | 6.1 | 64,479 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 18,850 | 0 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 18,850 | 28,354 (0%) | 0% | 0 | Common Stock | |
| Jean-Marc Bellemin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 18,850 | 0 | - | - | Restricted Stock Units | |
| Jean-Marc Bellemin | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.11 per share. | 03 Jan 2023 | 10,553 | 17,801 (0%) | 0% | 6.1 | 64,479 | Common Stock |
| Jean-Marc Bellemin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 18,850 | 28,354 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 19,690 | 32,571 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 19,690 | 0 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.11 per share. | 03 Jan 2023 | 11,023 | 21,548 (0%) | 0% | 6.1 | 67,351 | Common Stock |
| Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.15 per share. | 21 Dec 2022 | 10,000 | 70,150 (0%) | 0% | 6.2 | 61,500 | Common Stock |
| Wayne Rothbaum | Director | Purchase of securities on an exchange or from another person at price $ 6.50 per share. | 02 Dec 2022 | 10,000,000 | 18,067,333 (14%) | 7% | 6.5 | 65,000,000 | Common Stock |
| Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.31 per share. | 29 Nov 2022 | 10,000 | 238,633 (0%) | 0% | 6.3 | 63,100 | Common Stock |
| Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.18 per share. | 28 Nov 2022 | 10,000 | 228,633 (0%) | 0% | 6.2 | 61,800 | Common Stock |
| Frederick G. Vogt | Interim CEO & General Counsel | Purchase of securities on an exchange or from another person at price $ 5.98 per share. | 28 Nov 2022 | 1,000 | 2,000 (0%) | 0% | 6.0 | 5,980 | Common Stock |
| Iain D. Dukes | Director | Purchase of securities on an exchange or from another person at price $ 6.10 per share. | 23 Nov 2022 | 10,000 | 22,000 (0%) | 0% | 6.1 | 61,000 | Common Stock |
| Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2022 | 40,000 | 0 | - | - | Stock Option (right to buy) | |
| Merrill A. McPeak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.65 per share. | 23 Aug 2022 | 40,000 | 60,150 (0%) | 0% | 5.7 | 226,000 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 14 Jun 2022 | 9,346 | 9,504 (0%) | 0% | 7.7 | 72,245 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 18,850 | 18,850 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 18,850 | 18,850 (0%) | 0% | 0 | Common Stock | |
| Jean-Marc Bellemin | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 18,850 | 18,850 (0%) | 0% | 0 | Common Stock | |
| Jean-Marc Bellemin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 18,850 | 18,850 | - | - | Restricted Stock Units | |
| Jean-Marc Bellemin | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 14 Jun 2022 | 9,346 | 9,504 (0%) | 0% | 7.7 | 72,245 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 19,690 | 19,690 (0%) | 0% | 0 | Common Stock | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 14 Jun 2022 | 6,809 | 12,881 (0%) | 0% | 7.7 | 52,634 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 19,690 | 19,690 | - | - | Restricted Stock Units | |
| Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Michael Weiser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 102,409 | 102,409 | - | - | Deferred Restricted Stock Unit | |
| Frederick G. Vogt | Interim CEO & General Counsel | Purchase of securities on an exchange or from another person at price $ 6.44 per share. | 01 Jun 2022 | 1,000 | 1,000 (0%) | 0% | 6.4 | 6,440 | Common Stock |
| Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.80 per share. | 31 May 2022 | 10,000 | 218,633 (0%) | 0% | 6.8 | 68,000 | Common Stock |
| Merrill A. McPeak | Director | Purchase of securities on an exchange or from another person at price $ 6.84 per share. | 31 May 2022 | 10,000 | 20,150 (0%) | 0% | 6.8 | 68,400 | Common Stock |
| Michael Weiser | Director | Purchase of securities on an exchange or from another person at price $ 6.80 per share. | 31 May 2022 | 7,813 | 112,632 (0%) | 0% | 6.8 | 53,128 | Common Stock |
| Michael Weiser | Director | Purchase of securities on an exchange or from another person at price $ 6.79 per share. | 31 May 2022 | 2,187 | 104,819 (0%) | 0% | 6.8 | 14,850 | Common Stock |
| Ryan D. Maynard | Director | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 31 May 2022 | 7,500 | 7,500 (0%) | 0% | 6.7 | 50,588 | Common Stock |
| Wayne Rothbaum | Director | Purchase of securities on an exchange or from another person at price $ 6.43 per share. | 31 May 2022 | 500,000 | 8,067,333 (6%) | 0% | 6.4 | 3,215,500 | Common Stock |
| Wayne Rothbaum | Director | Purchase of securities on an exchange or from another person at price $ 6.77 per share. | 31 May 2022 | 500,000 | 7,567,333 (5%) | 0% | 6.8 | 3,384,550 | Common Stock |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 33,750 | 33,750 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 67,500 | 67,500 | - | - | Stock Option (right to buy) | |
| Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 250,000 | 250,000 | - | - | Restricted Stock Units | |
| Jean-Marc Bellemin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (right to buy) | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 33,750 | 33,750 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 67,500 | 67,500 | - | - | Stock Option (right to buy) | |
| Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Michael Weiser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 37,700 | 37,700 | - | - | Restricted Stock Units | |
| Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 73,900 | 73,900 | - | - | Stock Option (right to buy) | |
| Jean-Marc Bellemin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 37,700 | 37,700 | - | - | Restricted Stock Units | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 39,380 | 39,380 | - | - | Restricted Stock Units | |
| Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Maria Fardis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Michael Swartzburg | Vice President, Finance (PAO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Frederick G. Vogt | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Jean-Marc Bellemin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2020 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Merrill A. McPeak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Michael Weiser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Iain Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.12 per share. | 01 Jun 2020 | 1,894 | 298,786 (0%) | 0% | 33.1 | 62,729 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.00 per share. | 01 May 2020 | 1,894 | 300,680 (0%) | 0% | 32 | 60,608 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.94 per share. | 01 Apr 2020 | 1,494 | 302,574 (0%) | 0% | 27.9 | 41,742 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.99 per share. | 02 Mar 2020 | 1,321 | 304,068 (0%) | 0% | 36.0 | 47,543 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.54 per share. | 03 Feb 2020 | 1,302 | 305,389 (0%) | 0% | 22.5 | 29,347 | Common Stock |
| Maria Fardis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2020 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| Frederick G. Vogt | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2020 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2020 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.68 per share. | 02 Jan 2020 | 1,562 | 306,691 (0%) | 0% | 26.7 | 41,674 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.66 per share. | 01 Nov 2019 | 1,894 | 308,253 (0%) | 0% | 22.7 | 42,918 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.97 per share. | 01 Nov 2019 | 1,894 | 310,147 (0%) | 0% | 22.0 | 41,611 | Common Stock |
| Finckenstein Friedrich Graf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Merrill A. McPeak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Michael Weiser | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Ryan D. Maynard | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Athena Countouriotis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Iain Dukes | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Timothy E. Morris | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2019 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Maria Fardis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2019 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Frederick G. Vogt | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2019 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Iain Dukes | None | Purchase of securities on an exchange or from another person at price $ 8.65 per share. | 18 Dec 2018 | 12,000 | 12,000 (0%) | 0% | 8.6 | 103,796 | Common Stock |
| Merrill A. McPeak | None | Purchase of securities on an exchange or from another person at price $ 9.63 per share. | 13 Dec 2018 | 10,000 | 456,583 (0%) | 0% | 9.6 | 96,273 | Common Stock |
| Wayne Rothbaum | None | Purchase of securities on an exchange or from another person at price $ 10.31 per share. | 04 Dec 2018 | 921,053 | 6,767,333 (5%) | 0% | 10.3 | 9,496,056 | Common Stock |
| Wayne Rothbaum | None | Purchase of securities on an exchange or from another person at price $ 9.86 per share. | 04 Dec 2018 | 300,000 | 7,067,333 (5%) | 0% | 9.9 | 2,958,000 | Common Stock |
| Merrill A. McPeak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Michael Weiser | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Ryan D. Maynard | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Iain Dukes | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Michael Weiser | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2018 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Maria Fardis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2018 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| Frederick G. Vogt | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2017 | 37,400 | 37,400 | - | - | Stock Option (right to buy) | |
| Iain Dukes | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2017 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Timothy E. Morris | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2017 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Merrill A. McPeak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Sanford J. Hillsberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Ryan D. Maynard | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Jay Venkatesan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Iain Dukes | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.15 per share. | 03 Apr 2017 | 1,321 | 338,461 (0%) | 0% | 18.1 | 23,976 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.90 per share. | 03 Apr 2017 | 1,321 | 337,140 (0%) | 0% | 16.9 | 22,325 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Apr 2017 | 1,321 | 335,819 (0%) | 0% | 14.6 | 19,287 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.55 per share. | 03 Apr 2017 | 1,321 | 334,498 (0%) | 0% | 14.6 | 19,221 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.80 per share. | 03 Apr 2017 | 1,321 | 333,177 (0%) | 0% | 12.8 | 16,909 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.70 per share. | 03 Apr 2017 | 1,321 | 331,856 (0%) | 0% | 13.7 | 18,098 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.10 per share. | 03 Apr 2017 | 1,321 | 330,535 (0%) | 0% | 17.1 | 22,589 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.12 per share. | 03 Apr 2017 | 1,321 | 329,214 (0%) | 0% | 11.1 | 14,690 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.62 per share. | 03 Apr 2017 | 1,321 | 327,893 (0%) | 0% | 9.6 | 12,708 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.44 per share. | 03 Apr 2017 | 1,321 | 326,572 (0%) | 0% | 10.4 | 13,791 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.15 per share. | 03 Apr 2017 | 51,673 | 498,327 (0%) | 0% | 7.2 | 369,462 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.26 per share. | 03 Apr 2017 | 1,562 | 323,448 (0%) | 0% | 9.3 | 14,464 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.77 per share. | 03 Apr 2017 | 1,298 | 322,150 (0%) | 0% | 10.8 | 13,979 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.78 per share. | 03 Apr 2017 | 1,321 | 320,829 (0%) | 0% | 9.8 | 12,919 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.14 per share. | 03 Apr 2017 | 1,321 | 319,508 (0%) | 0% | 11.1 | 14,716 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.04 per share. | 03 Apr 2017 | 1,321 | 318,187 (0%) | 0% | 18.0 | 23,831 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 03 Apr 2017 | 1,321 | 316,866 (0%) | 0% | 24.6 | 32,523 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.17 per share. | 03 Apr 2017 | 1,321 | 315,545 (0%) | 0% | 25.2 | 33,250 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.27 per share. | 03 Apr 2017 | 1,610 | 313,935 (0%) | 0% | 20.3 | 32,635 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.21 per share. | 03 Apr 2017 | 1,894 | 312,041 (0%) | 0% | 18.2 | 34,490 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.45 per share. | 03 Apr 2017 | 1,562 | 325,010 (0%) | 0% | 9.5 | 14,761 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.45 per share. | 03 Apr 2017 | 143,496 | 354,831 (0%) | 0% | 5.4 | 782,053 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.35 per share. | 03 Apr 2017 | 1,994 | 352,837 (0%) | 0% | 7.4 | 14,656 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.70 per share. | 03 Apr 2017 | 1,993 | 350,844 (0%) | 0% | 5.7 | 11,360 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.00 per share. | 03 Apr 2017 | 1,994 | 348,850 (0%) | 0% | 6 | 11,964 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.75 per share. | 03 Apr 2017 | 1,993 | 346,857 (0%) | 0% | 7.8 | 15,446 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.15 per share. | 03 Apr 2017 | 1,994 | 344,863 (0%) | 0% | 7.1 | 14,257 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.80 per share. | 03 Apr 2017 | 1,994 | 342,869 (0%) | 0% | 8.8 | 17,547 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.00 per share. | 03 Apr 2017 | 1,562 | 341,307 (0%) | 0% | 8 | 12,496 | Common Stock |
| Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.50 per share. | 03 Apr 2017 | 1,525 | 339,782 (0%) | 0% | 16.5 | 25,163 | Common Stock |
| Gregory T. Schiffman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2016 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Sanford J. Hillsberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 24 Aug 2016 | 20,500 | 100,000 | - | - | Common Stock | |
| Sanford J. Hillsberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 24 Aug 2016 | 33,500 | 120,500 | - | - | Common Stock | |
| Merrill A. McPeak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2016 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Sanford J. Hillsberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2016 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Ryan D. Maynard | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2016 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Jay Venkatesan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2016 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Iain Dukes | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2016 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2016 | 50,000 | 50,000 | - | - | Stock Option | |
| Molly Henderson | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2016 | 150,000 | 150,000 | - | - | Stock Option | |
| Maria Fardis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2016 | 550,000 | 550,000 | - | - | Common Stock | |
| Maria Fardis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2016 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| Michael Lotze | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2016 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Elma S. Hawkins | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2016 | 275,000 | 275,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2016 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| James G. Bender | Vice President - Manufacturing | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2016 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Steven A. Fischkoff | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2016 | 225,000 | 225,000 | - | - | Stock Option | |
| Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2015 | 21,116 | 21,116 | - | - | Stock Option (right to buy) | |
| James G. Bender | Vice President, Manufacturing | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2015 | 27,622 | 27,622 | - | - | Stock Option (right to buy) | |
| James G. Bender | Vice President, Manufacturing | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 30 Sep 2015 | 11,274 | 88,726 | - | - | Common Stock | |
| Sanford J. Hillsberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 04 Sep 2015 | 16,000 | 170,500 | - | - | Common Stock | |
| Sanford J. Hillsberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 04 Sep 2015 | 16,500 | 154,000 | - | - | Common Stock | |
| Sanford J. Hillsberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 03 Aug 2015 | 32,500 | 186,500 | - | - | Common Stock | |
| Merrill A. McPeak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2015 | 35,000 | 35,000 | - | - | Common Stock | |
| Sanford J. Hillsberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2015 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Ryan D. Maynard | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2015 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Jay Venkatesan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2015 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Molly Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2015 | 200,000 | 200,000 | - | - | Stock Option | |
| Sanford J. Hillsberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 06 May 2015 | 50,000 | 219,000 | - | - | Common Stock | |
| Elma S. Hawkins | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2015 | 40,000 | 160,000 | - | - | Restricted Stock | |
| Elma S. Hawkins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2015 | 58,939 | 58,939 | - | - | Stock Option (right to buy) | |
| Elma S. Hawkins | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2015 | 40,000 | 200,555 | - | - | Common Stock | |
| Elma S. Hawkins | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 28 Feb 2015 | 23,988 | 176,567 | - | - | Common Stock | |
| Martin Schroeder | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Aug 2011 | 1,000,000 | 1,000,000 | - | - | Common Stock | |
| Merrill A. McPeak | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 21 Jul 2011 | 10,000 | 10,000 | - | - | Common Stock | |
| Anthony J. Cataldo | Director, CEO, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2011 | 3,000,000 | 3,000,000 | - | - | Common Stock | |
| Robert Brooke | Director, President, CEO, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2010 | 2,000,000 | 7,940,008 | - | - | Common Stock | |
| Robert Brooke | Director, President, CEO, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2010 | 2,000,000 | 5,940,008 | - | - | Common Stock |